Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision dosing strategies for vancomycin and polymyxin B in acute kidney injury high-risk patients with resistant bacterial infections
ChiCTR2000036579Phase 4Not yet recruiting
- Sponsor
- Jing Zhang
- Start
- Oct 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin and polymyxin B in bacterial disease, Staphylococcus aureus infection, Methicillin-resistant Gram-positive bacterial infection and 1 more (2 arms), sponsored by Jing Zhang. Primary endpoints: Plasma drug concentration, Pathogen minimum inhibitory concentration and 2 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
vancomycinpolymyxin B
03
Conditions
bacterial diseaseStaphylococcus aureus infectionMethicillin-resistant Gram-positive bacterial infectionGram-negative bacterial infection
Beyond the preview
Go deeper on ChiCTR2000036579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036579.